Effect and mechanism of allergen-specific immunotherapy on small airway dysfunction in children with asthma

被引:0
|
作者
Zhong, Wenwei [1 ]
Ying, Xiaolan [2 ]
Zhang, Lei [2 ]
Dong, Wenfang [2 ]
Lin, Jie [2 ]
Yang, Lin [3 ]
Hong, Li [3 ,4 ]
Yin, Yong [2 ]
Wu, Jinhong [2 ]
机构
[1] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Pediat, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Resp Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Clin Nutr, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Lab Dept, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
allergen-specific immunotherapy; asthma; basophil; child; small airway dysfunction; SUBCUTANEOUS IMMUNOTHERAPY; EFFICACY; SAFETY;
D O I
10.1002/ppul.27341
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: The purpose of this study was to investigate the effectiveness of allergen-specific immunotherapy (AIT) on small airway dysfunction (SAD) and the underlying mechanism with a special focus on basophils. Methods: Sixty-five children with mild to moderate asthma who were under regular inhaled corticosteroid (ICS) treatment for more than 1 year but whose FEF75 remained below 65% of the predicted value and had positive results for serum Der p or Der f were enrolled. Children with asthma underwent house dust mite (HDM) subcutaneous immunotherapy (SCIT) treatment for 1 year. Clinical symptoms and lung function were evaluated every 3 months during HDM SCIT treatment. Basophil activation test (BAT) was carried out before and after HDM SCIT treatment. RNA sequencing was performed in isolated basophils from peripheral blood after 6 months of HDM SCIT treatment, followed by GO term and KEGG pathway enrichment analysis between patients with and without HDM SCIT treatment. Results: HDM AIT treatment ameliorated clinical symptoms while concurrently improved lung function parameters, such as FEV1/FVC, FEF75, FEF50 and MMEF (p < .05). It is worth noting that FEF75 values showed a highly significant, gradual and persistent increase (from 49.55 +/- 1.27% at baseline to 71.89 +/- 2.64% after 1 year of therapy) and 22 of 35 patients no longer had SAD after 1 year of treatment. BAT results revealed that AIT treatment significantly reduced basophil activity to the inhalant allergen mixtures containing HDM in vitro challenge from baseline. GO term and KEGG pathway enrichment analysis of basophils revealed that downregulated genes were mainly involved in immune cell activation, antigen presentation, and Th2 cell differentiation. Conclusions: Our study demonstrated that HDM AIT not only improved SAD related lung function parameters, but also reduced basophil activity. RNA sequencing revealed the inhibition of phagocytosis and the phagosome pathway in basophils which may affect the polarization of Th2 cell differentiation after HDM AIT.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The Future of Allergen-Specific Immunotherapy
    Marek Jutel
    Katarzyna Solarewicz-Madejek
    Sylwia Smolińska
    Drug information journal : DIJ / Drug Information Association, 2012, 46 : 683 - 687
  • [42] Allergen-specific immunotherapy in Georgia
    Rukhadze, M.
    Dolidze, N.
    Abramidze, T.
    Lomidze, N.
    Gotua, M.
    Gamkrelidze, A.
    ALLERGY, 2008, 63 : 529 - 529
  • [43] Advances in Allergen-Specific Immunotherapy
    Passalacqua, Giovanni
    Compalati, Enrico
    Canonica, Giorgio Walter
    CURRENT DRUG TARGETS, 2009, 10 (12) : 1255 - 1262
  • [44] Adjuvants in Allergen-Specific Immunotherapy
    Gajdanowicz, P.
    Pfaar, O.
    Jutel, M.
    ALLERGOLOGIE, 2018, 41 (09) : 427 - 434
  • [45] Novel Administration Routes for Allergen-Specific Immunotherapy: A Review of Intralymphatic and Epicutaneous Allergen-Specific Immunotherapy
    von Moos, Seraina
    Kuendig, Thomas M.
    Senti, Gabriela
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2011, 31 (02) : 391 - +
  • [46] Allergen-specific immunotherapy with mRNAvaccines reduces allergic airway inflammation in mice
    Li, Junda
    Li, Xiaogang
    Guan, Kai
    Yin, Jia
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB288 - AB288
  • [47] Mechanisms of allergen-specific immunotherapy and allergen tolerance
    Kucuksezer, Umut C.
    Ozdemir, Cevdet
    Cevhertas, Lacin
    Ogulur, Ismail
    Akdis, Mubeccel
    Akdis, Cezmi A.
    ALLERGOLOGY INTERNATIONAL, 2020, 69 (04) : 549 - 560
  • [48] Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: A randomized controlled trial
    Zielen, Stefan
    Kardos, Peter
    Madonini, Enzo
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 126 (05) : 942 - 949
  • [49] Effect of immunotherapy on allergen-specific production of sulphidoleukotriene and histamine
    Ferrer, M
    Sanz, ML
    Prieto, I
    Vila, L
    Oehling, A
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY, 1998, 8 (05): : 277 - 280
  • [50] Allergen-specific subcutaneous immunotherapy in allergic asthma: immunologic mechanisms and improvement
    Taher, Yousef A.
    Henricks, Paul A. J.
    van Oosterhout, Antoon J. M.
    LIBYAN JOURNAL OF MEDICINE, 2010, 5